Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 501–600 of 910
Indian rheumatology association guidelines for management of glucocorticoid-induced osteoporosis
Krishnamurthy, V., Sharma, A., Aggarwal, A., Kumar, U., Amin, S. N., Rao, U. R., Narsimulu, G., Handa, R., Mithal, A., & Joshi, S. (2011) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(11)60060-5 · Cited by 10
Spotlight on Teriparatide in Osteoporosis†
Blick, S. K. A., Dhillon, S., & Keam, S. J. (2009) · BioDrugs · doi:10.2165/00063030-200923030-00006 · Cited by 8
Anagnostis, P. G., Efstathiadou, Z. A., Akriviadis, E. A., Hytiroglou, P., & Kita, M. D. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1848-y · Cited by 8
Marco, E., Coll-Fernández, R., Marín, M., Coll-Fernández, R., Pascual, M. T., Resa, J., Muñoz, L., Romero, M., Burnham, P., & Ciria, M. (2016) · Rehabilitación · doi:10.1016/j.rh.2016.04.004 · Cited by 11
Glucocorticoid-induced Osteoporosis
Mazziotti, G., & Giustina, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00034-1 · Cited by 10
Pediatric CKD-MBD: existing and emerging treatment approaches
Ayoob, R. M., & Mahan, J. D. (2022) · Pediatric Nephrology · doi:10.1007/s00467-021-05265-8 · Cited by 13
Assessing bone loss in micro-gravity: A fuzzy approach
Zobel, B. B., Vescovo, R. D., Oliva, G., Russo, V., & Setola, R. (2012) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2012.05.001 · Cited by 9
Rheumatologic sequelae and challenges in organ transplantation
Schwab, P., Lipton, S., & Kerr, G. S. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.12.011 · Cited by 8
Liu, Y., Yang, C., Li, Z., Zhou, J., Lv, Y., Zhang, Y., Zeng, F., & Shi, S. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.03.015 · Cited by 8
Appropriate use of anabolic treatment for severe osteoporosis.
Adami, S., Brandi, M. L., Canonico, P. L., Minisola, G., Minisola, S., & Tarantino, U. (2010) · PubMed · Cited by 8
Nogués, X., Rentero, M. L., & Rodríguez, A. L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.851659 · Cited by 8
Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.
Santiago, T., Jacobs, J. W. G., Saag, K. G., Buttgereit, F., & da Silva, J. A. P. (2015) · PubMed · Cited by 8
Self-citationMechanisms and therapeutics of glucocorticoid-induced osteoporosis.
Kaneko, K., & Kawai, S. (2011) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.34.138 · Cited by 9
Geng, Q., Heng, K., Li, J., Wang, S., Sun, H., Sha, L., Guo, Y., Nie, X., Wang, Q., Dai, L., et al. (2019) · PubMed · Cited by 12
Giusti, A., & Bianchi, G. (2014) · Reumatismo · doi:10.4081/reumatismo.2014.786 · Cited by 8
Leitliniengerechte Diagnostik und Therapie der Osteoporose 2010
Braun, J. M., & Pfeilschifter, J. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0623-3 · Cited by 8
Chapter 58. Glucocorticoid‐Induced Osteoporosis
Weinstein, R. S. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch58 · Cited by 12
Romosozumab for the treatment of postmenopausal women at high risk of fracture
Geusens, P., Appelman‐Dijkstra, N. M., Lems, W. F., & van den Bergh, J. P. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2152320 · Cited by 7
Larraz‐Prieto, B., Lind, L. H., Olesen, J. B., Azfer, A., Hansen, M. S., Frost, M., Jafari, A., Ralston, S. H., Søe, K., & Alonso, N. (2025) · Bone and Joint Research · doi:10.1302/2046-3758.145.bjr-2024-0167.r1 · Cited by 7
Ambrosi, T. H., Morales, D., Chen, K., Hunt, E. J., Weldon, K. C., Maifeld, A. N., Chávez, F. S., Wang, Y., Zhao, L., Wang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62881-w · Cited by 7
Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice
Krüger, B. T., Steppe, L., Vettorazzi, S., Haffner‐Luntzer, M., Lee, S., Dorn, A.-K., Ignatius, A. A., Tuckermann, J. P., & Ahmad, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020404 · Cited by 8
Brance, M. L., Larroudé, M. S., Zamora, N. V., Bagur, A., Graf, C. E., Giacoia, E., Diehl, M., Somma, L. F., Schneeberger, E. E., Salerni, H. H., et al. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001951 · Cited by 8
Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict
Rothman, M. S., Olenginski, T. P., Stanciu, I., Krohn, K., & Lewiecki, E. M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05147-8 · Cited by 8
Vertebral Fractures in Ireland: A Sub-analysis of the DXA HIP Project
Carey, J. J., Yang, L., Erjiang, E., Wang, T., Gorham, K., Egan, R., Brennan, A., Dempsey, M., Armstrong, C., Heaney, F., et al. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00868-7 · Cited by 7
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist
Chakrabarti, K., & McCune, W. J. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000934 · Cited by 7
Osteoporosis in young individuals
Bernal, P. P. (2010) · Reumatología Clínica (English Edition) · doi:10.1016/s2173-5743(10)70048-4 · Cited by 12
Hall, S. L., Chen, S., Gysin, R., Gridley, D. S., Mohan, S., & Lau, K. ‐. W. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1369 · Cited by 7
Atypical metatarsal fracture in a patient on long term bisphosphonate therapy
Pradhan, P., Saxena, V., Yadav, A. K., & Mehrotra, V. (2012) · Indian Journal of Orthopaedics · doi:10.4103/0019-5413.101048 · Cited by 7
Bilateral Pathological Hip Fractures in a Patient with a Bipulmonary Transplant: A Case Report
Seijas, R., Ares, Ó., Malik, A., & Maled, I. (2009) · Journal of orthopaedic surgery · doi:10.1177/230949900901700227 · Cited by 7
Lv, F., Guan, Y., Ma, D., Xu, X., Song, Y., Li, L., Jiang, Y., Wang, O., Xia, W., Xing, X., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13537 · Cited by 7
Systemic Glucocorticoid Therapy in SLE
Kirou, K. A., & Boumpas, D. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1893-5.00048-0 · Cited by 8
Male osteoporosis: new insights in an understudied disease
Haney, E. M., & Bliziotes, M. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e3283154ed4 · Cited by 7
Axelrod, L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00100-3 · Cited by 8
Glucocorticoid-Induced Osteoporosis
Dubrovsky, A., Maricic, M. J., & Lane, N. E. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_21 · Cited by 6
Bone and the cAMP Signaling Pathway: Emerging Therapeutics
Epstein, P. M. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_16 · Cited by 7
Osteoporose – Was ist gesichert in der Therapie?
Jehle, P. M., & Pfeilschifter, J. (2009) · Der Internist · doi:10.1007/s00108-009-2460-5 · Cited by 7
Naranjo, A., López, R., Garcia-Magallón, B., Cáceres, L., Francisco, F., Jiménez-Palop, M., & Ojeda-Bruno, S. (2014) · Rheumatology International · doi:10.1007/s00296-014-3014-2 · Cited by 7
Taştekin, N., & Zateri, Ç. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27427 · Cited by 7
Wang, X., Sato, A. Y., Marino, S., Akel, N. S., Boysen, G., Basnakian, A. G., Bellido, T., & Li, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02539 · Cited by 6
Lee, S., Hong, N., Cho, S., Shin, S., & Rhee, Y. (2025) · Osteoporosis International · doi:10.1007/s00198-024-07336-6 · Cited by 6
First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity
Aleksova, J., & Ebeling, P. R. (2025) · Internal Medicine Journal · doi:10.1111/imj.70061 · Cited by 7
Kishimoto, Y., Kato, Y., Uemura, M., & Kuranobu, K. (2022) · BMC Rheumatology · doi:10.1186/s41927-021-00243-x · Cited by 5
Teriparatide-Associated Late Hypercalcemia: A Report of Two Cases and Literature Review
Milosavljevic, J., & Thomas, A. M. (2022) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1010 · Cited by 10
Peptide and peptide-based drugs
Wang, L., Wang, N., Yan, Z., Huang, Z., & Fu, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00015-2 · Cited by 7
Current indications for prevention and therapy of steroid-iduced osteoporosis in men and women.
Sewerynek, E. (2011) · PubMed · Cited by 6
Newer therapies in osteoporosis
Kanakamani, J., & Tandon, N. (2008) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60141-0 · Cited by 8
Treatment of osteoporosis in children with glucocorticoid-treated diseases
Faienza, M. F., Luce, V., Lonero, A., Ventura, A., Colaianni, G., Colucci, S. C., Cavallo, L., Grano, M., & Brunetti, G. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.936384 · Cited by 7
Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study
Wright, N. C., Foster, P. J., Mudano, A. S., Melnick, J. A., Lewiecki, M. E., Shergy, W. J., Curtis, J. R., Cutter, G., Danila, M. I., Kilgore, M. L., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4073-5 · Cited by 6
Self-citationOki, S., Nonaka, T., & Shiraki, K. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.02.001 · Cited by 6
Uei, H., Tokuhashi, Y., Maseda, M., Nakahashi, M., & Nakayama, E. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4425-9 · Cited by 6
Pragmatic Clinical Trials in Osteoporosis
Adami, G., Saag, K. G., & Danila, M. I. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00551-9 · Cited by 7
Self-citationGlucocorticoid-Induced Osteoporosis
Adler, R. A., Weinstein, R. S., & Saag, K. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00049-2 · Cited by 6
Self-citationGlucocorticoid-induced osteoporosis
Sambrook, P. N. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00198-6 · Cited by 7
Kriel, M. H., Sayers, A. E., Fraser, W. D., Williams, A. M., Koch, A. H., Zacharowski, K. D., Probert, C. S., & Tobias, J. H. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9345-4 · Cited by 7
Chapter 51. Parathyroid Hormone Treatment for Osteoporosis
Cosman, F., & Greenspan, S. L. (2008) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9780470623992.ch51 · Cited by 6
Haroon, S., Cobb, C., Sufian, S., Jain, R., Maalouf, N. M., & Putman, M. S. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.011 · Cited by 6
Tang, J., Gong, D., Li, H., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.039 · Cited by 7
Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta
Hald, J. D., Weir, C. J., Keerie, C., Dewar, L., MacLean, M., Milne, L., Keen, R. W., Walsh, J., Poole, K. E. S., Langdahl, B. L., et al. (2026) · JAMA · doi:10.1001/jama.2026.6889 · Cited by 5
Improvement of bone strength with teriparatide: hip as well as spine?
Ferrari, S. (2012) · IBMS BoneKEy · doi:10.1038/bonekey.2012.175 · Cited by 5
Pharmacological treatment of osteoporosis: 2022 update
Jeon, Y. K., & Kim, I. J. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.4.241 · Cited by 5
Iki, M., Fujimori, K., Nakatoh, S., Tamaki, J., Ishii, S., Okimoto, N., Kamiya, K., & Ogawa, S. (2022) · Bone · doi:10.1016/j.bone.2022.116605 · Cited by 6
Yamasaki, S. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05266-7 · Cited by 7
Understanding Osteoporosis: Pathophysiology, Risk Factors, Diagnosis, and Management
Ismail, M. (2024) · Advances in Aging Research · doi:10.4236/aar.2024.133003 · Cited by 8
Osteoporose – aktuelle Diagnostik und Therapie
Pfeilschifter, J. (2009) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-009-1135-2 · Cited by 5
Grundlagen und Management der glukokortikoidinduzierten Osteoporose
Willenberg, H. S., & Lehnert, H. (2008) · Der Internist · doi:10.1007/s00108-008-2118-8 · Cited by 7
Current Controversies in Bisphosphonate Therapy
Kamath, A. F. (2009) · Orthopedics · doi:10.3928/01477447-20090527-03 · Cited by 4
Srinivasulu, N., Sharma, V., Chitnis, N., Mangat, G., Samant, R., & Balakrishnan, C. (2010) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(11)60005-8 · Cited by 5
Sewerynek, E., & Stuss, M. (2012) · Aging Health · doi:10.2217/ahe.12.52 · Cited by 5
Osteoporosis: Prevention and Treatment
Zaheer, S., & LeBoff, M. S. (2016) · Cited by 8
Osteoporosis in Premenopausal Women
Liu, M., Nair, N., & Cohen, A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_23 · Cited by 5
Denosumab for glucocorticoid-induced osteoporosis
Reid, I. R. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0035-z · Cited by 5
Management of glucocorticoid‐induced osteoporosis: What is new?
Compston, J. E. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13680 · Cited by 5
Osteoporosis in neurological disorders: Parkinson’s disease, stroke, and multiple sclerosis
Oleson, C. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00041-1 · Cited by 5
A pilot study comparing daily teriparatide with monthly cycles of teriparatide and raloxifene
Goel, H., Libber, J., Borchardt, G. J., Krueger, D. C., & Binkley, N. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00933-6 · Cited by 5
Rizzoli, R. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0838 · Cited by 5
Ruyssen‐Witrand, A., Mouterde, G., Dernis, E., Gaudin, P., Wendling, D., Cantagrel, A. G., Claudepierre, P., Fautrel, B., Maillefert, J.-F., Saraux, A., et al. (2008) · Revue du Rhumatisme · doi:10.1016/s1169-8330(08)70010-3 · Cited by 6
Hoblitzell, A., Mukhopadhyay, S., You, Q., Fang, S., Xia, Y., & Bidwell, J. P. (2010) · ACM International Symposium on High-Performance Parallel and Distributed Computing (HPDC) · doi:10.1145/1851476.1851552 · Cited by 5
Management of Osteoporosis: Who to Treat, What to Use, and for How Long?
Kim, S. W. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.85.4.364 · Cited by 5
Mohd‐Tahir, N., Thomas, P., Mohamed‐Said, M., Makmor‐Bakry, M., & Li, S. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13206 · Cited by 5
Management of corticosteroid-induced osteoporosis
(2010) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2010.09.0047 · Cited by 5
Transcutaneous Raman Spectroscopy of Bone
Maher, J. R. (2013) · UR Research (University of Rochester) · Cited by 5
The Growing Significance of microRNAs in Osteoporosis
Sarkar, A., Sarkar, S., Anwar, A., Kim, J. W., Shim, J., & John, A. A. (2025) · Cells · doi:10.3390/cells14231905 · Cited by 6
Yee, C. S., Meliadis, C., Kaya, S., Chang, W., & Alliston, T. N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1342938 · Cited by 6
Ghielmetti, A., Grassi, G., Zampogna, M., Mantovani, G., Chiodini, I., & Eller-Vainicher, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186360 · Cited by 4
Glucocorticoids, Inflammation, and Bone
Ng, K. W., & Martin, T. J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_7 · Cited by 5
Current Knowledge, Drug-Based Therapeutic Options and Future Directions in Managing Osteoporosis
Moshiri, A., Sharifi, A. M., & Oryan, A. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-016-9207-3 · Cited by 6
Parathyroid hormone for osteoporosis treatment
Lin, W.-P., & Lin, J. (2011) · Formosan Journal of Musculoskeletal Disorders · doi:10.1016/j.fjmd.2011.09.001 · Cited by 6
The Elderly Inflammatory Bowel Disease Patient and Osteoporosis
Katz, S., & Weinerman, S. A. (2012) · Aging Health · doi:10.2217/ahe.11.86 · Cited by 4
Iwamoto, J., Seki, A., & Sato, Y. (2014) · The Chinese Journal of Physiology · doi:10.4077/cjp.2014.bac242 · Cited by 4
RetractedPrevention and Treatment of Bone Disease in Systemic Lupus Erythematosus
Lin, T. K., & Grossman, J. M. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0034-y · Cited by 4
Osteoporose: Leitliniengerechte Prophylaxe, Diagnostik und Therapie
Lange, U., Müller‐Ladner, U., & Pfeilschifter, J. (2011) · Der Internist · doi:10.1007/s00108-011-2851-2 · Cited by 5
Goltzman, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00009-6 · Cited by 4
Marín, F., & Li, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_22 · Cited by 5
Self-citationThe Risk Factors for Developing Clustered Vertebral Compression Fractures: A Single-Center Study
Wang, X., Jiang, J., Guan, W., Yu, W., Xu, T., Li, M., & Zhang, J. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.011 · Cited by 5
Tanaka, I., Tanaka, Y., Soen, S., & Oshima, H. (2021) · Modern Rheumatology · doi:10.1093/mr/roab034 · Cited by 4
Gout in Primary Hyperparathyroidism, Connecting Crystals to the Minerals
Mittal, M., Patra, S., Saxena, S., Roy, A., Yadav, T., & Vedant, D. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac018 · Cited by 4
Brance, M. L., Larroudé, M. S., Somma, L. F., Giacoia, E., Diehl, M., Galich, A. M., Stieben, L. A. R., Maher, M. C., Vega, M. D. L., Ringer, A., et al. (2022) · Reumatología Clínica · doi:10.1016/j.reuma.2022.10.002 · Cited by 4
Kong, M., Gao, C., Luan, X., Fan, C., Hao, M., Jin, C., Zhao, J., Li, H., Zhao, J., Luan, J., et al. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07227-1 · Cited by 6
Lane, N. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00101-7 · Cited by 5
Characteristics of Parathyroid hormone-1 Receptor Agonists and Antagonists
Zhong, Y., Li, X., Zhu, D., Zhao, N., Yao, H., & Lin, K. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0508 · Cited by 4
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.